Novo Nordisk's top executive faced a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the ...
Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But CEO Lars Fruergaard Jørgensen has defended the company, attributing the ...
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...